Fogarty International Center; Notice of Meeting, 24318-24319 [07-2144]
Download as PDF
<![CDATA[
24318
Federal Register / Vol. 72, No. 84 / Wednesday, May 2, 2007 / Notices
mmaher on DSK3CLS3C1PROD with $$_JOB
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Diagnosing and Treating Cancer Using
Beta-Catenin Splice Variants
Description of Technology: This
application discloses and claims
inventions which may be used alone or
together. One group of inventions
relates to early detection diagnostic,
prognostic and patient monitoring
methods (‘‘Diagnostic Methods’’). The
other group of inventions relates to
methods of treatment. Both groups of
inventions have particular application
with respect to esophageal squamous
cell cancers (ESCC) or other types of
adenocarcinomas and squamous cell
carcinomas.
The Diagnostic Methods are useful in
evaluating the status of preneoplastic
lesions as well as tumor tissue. Because
of this, the methods can be used to track
the progression or regression of disease
in many types of cell samples from
normal to dysplasia to cancer.
The Diagnostic Methods involve
measuring the level of one or more pairs
of transcripts or the protein products of
these pairs of transcripts or the cellular
localization of the transcripts or
proteins. The primary transcripts or
protein products useful in this method
are those of the beta-Catenin gene
(CTNNB1). In particular, the levels of
the 16A and 16B CTNNB1 transcripts or
protein products are of importance in
carrying out the methods of this patent
application. Other gene transcripts or
protein products that may be used in
conjunction with CTNNB1 16A and 16B
to provide additional information are
WAF1 (p21) and cMYC.
The treatment methods include
employing small interfering RNA
molecules (siRNAs) as a means to alter
the expression of one or more of these
VerDate Mar 15 2010
03:08 Aug 19, 2011
Jkt 223001
particular CTNNB1 transcripts. More
specifically, preferred siRNA molecules
can be used to alter the expression of
the CTNNB1 transcripts 16A and/or
16B. These siRNA molecules may be
single-stranded (ss) or double-stranded
(ds) and may be delivered using a
construct capable of producing the
siRNA molecule upon delivery to the
target cell.
Applications: Diagnostic or prognostic
methods for squamous cell cancers and
adenocarcinomas; Monitoring
therapeutic response during and after
patient treatment; Development of
cancer treatments; Basic research to
further elucidate the role of beta catenin
in signal transduction pathways and
carcinogenesis.
Development Stage: The use of beta
catenin transcripts to provide prognostic
or diagnostic information remains the
subject of research but early patient data
is found in the article in Genes
Chromosomes & Cancer listed below.
Work related to the use of siRNA as a
treatment strategy remains in its early
stages of research and has not yet
progressed to clinical trials.
Inventors: Mark J. Roth and Konrad
Huppi (NCI).
Publications:
1. The patent application has been
published as WO 2006/086772 A2 on 17
August 2006.
2. MJ Roth et al. beta-Catenin splice
variants and downstream targets as
markers for neoplastic progression of
esophageal cancer. Genes Chromosomes
Cancer. 2005 Dec;44(4):423–428.
3. SE Martin et al. Multiplexing
siRNAs to compress RNAi-based screen
size in human cells. Nucleic Acids Res.
2007 Mar 28; E published ahead of
print, doi:10.1093/nar/gkm141.
4. A Thiele et al. AU-rich elements
and alternative splicing in the betaCatenin 3’ UTR can influence the
human beta-Catenin mRNA stability.
Exp Cell Res. 2006 Jul;312:2367–2378.
Patent Status:
PCT/US2006/05032 filed 10 Feb 2006
and published as WO 2006/086772 on
17 Aug 2006, currently pending,
entitled ‘‘Method of Diagnosing and
Treating Cancer Using Beta Catenin
Splice Variants’’ (HHS Reference No. E–
018–2005/2–PCT–01);
U.S. Provisional Application No. 60/
667,084 filed 30 Mar 2005, now
abandoned (HHS Reference No. E–018–
2005/1–US–01);
U.S. Provisional Application No. 60/
652,154 filed 10 Feb 2005, now
abandoned (HHS Reference No. E–018–
2005/0–US–01).
Biological Materials Availability:
Biological materials related to this
technology are available and include
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
those referred to in the following
publications as well as a series of
recently established aptamers capable of
specific binding to the CTNNB1 protein.
1. MJ Roth et al. Cytologic detection
of esophageal squamous cell carcinoma
and precursor lesions using balloon and
sponge samplers in asymptomatic adults
in Linxian, China. Cancer. 1997 Dec
1;80(11):2047–2059.
2. Q–J Pan et al. Cytologic detection
of esophageal squamous cell carcinoma
and its precursor lesions using balloon
samplers and liquid-based cytology in
asymptomatic adults in Linxian, China.
ACTA Cytologica (In Press).
3. MJ Roth et al. A study of betacatenin splice variants and associated
downstream targets as markers for
neoplastic progression of squamous cell
carcinoma of the esophagus. Genes
Chromosomes Cancer. 2005
Dec;44(4):423–428.
4. PJ Limburg et al. Randomized,
placebo-controlled esphogeal squamous
cell cancer chemoprevention trial of
selenomethionine and celecoxib.
Gastroenterology. 2005 Sept;129(3):863–
873.
Licensing Availability: This
application is available for license on a
non-exclusive or exclusive basis.
Licensing Contact: Susan S. Rucker,
Esq.; 301/435–4478;
ruckersu@mail.nih.gov
Collaborative Research Opportunity:
The National Cancer Institute, Division
of Cancer Epidemiology and Genetics, is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate, or commercialize a
method of diagnosing and treating
cancer using beta-Catenin splice
variants. Please contact John D. Hewes,
PhD at 301–435–3121 or
hewesj@mail.nih.gov for more
information. 8356
Dated: April 25, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E7–8356 Filed 5–1–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Fogarty International Center; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the
E:\FEDREG\02MYN1.LOC
02MYN1
Federal Register / Vol. 72, No. 84 / Wednesday, May 2, 2007 / Notices
mmaher on DSK3CLS3C1PROD with $$_JOB
Fogarty International Center Advisory
Board.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Fogarty International
Center Advisory Board.
Date: May 21–22, 2007.
Closed: May 21, 2007, 1 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: National Institutes of Health,
Lawton Chiles International House, Bethesda,
MD 20892.
Open: May 22, 2007, 8:30 a.m. to 5 p.m.
Agenda: Fogarty International Center will
present an early draft of the Strategic Plan.
Place: National Institutes of Health,
Lawton Chiles International House, Bethesda,
MD 20892.
Contact Person: Jean L. Flagg-Newton,
Ph.D., Special Assistant to the Director, FIC,
Fogarty International Center, National
Institutes of Health, 9000 Rockville Pike,
Building 31, Room B2C29, Bethesda, MD
20892, (301) 496–2968,
flaggnej@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page: https://
www.nih.gov/fic/about/advisory.html, where
an agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.106, Minority International
VerDate Mar 15 2010
03:08 Aug 19, 2011
Jkt 223001
Research Training Grant in the Biomedical
and Behavioral Sciences; 93.154, Special
International Postdoctoral Research Program
in Acquired Immunodeficiency Syndrome;
93.168, International Cooperative
Biodiversity Groups Program; 93.934, Fogarty
International Research Collaboration Award;
93.989, Senior International Fellowship
Awards Program, National Institutes of
Health, HHS)
Dated: April 24, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–2144 Filed 5–1–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the
National Cancer Advisory Board.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
A portion of the meeting will be
closed to the public in accordance with
the provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Advisory Board.
Date: June 14, 2007, 2 p.m. to 4:30 p.m.
Agenda: Program reports and
presentations; Business of the Board.
Place: National Cancer Institute, 9000
Rockville Pike, building 31, C Wing, 6th
Floor, Conference Room 10, Bethesda, MD
20892.
Contact Person: Dr. Paulette, S. Gray,
Executive Secretary, National Cancer
Institute, National Institutes of Health, 6116
Executive Boulevard, 8th Floor, Room 8001,
Bethesda, MD 20892–8327, (301) 496–5147.
Name of Committee: National Cancer
Advisory Board.
Date: June 14, 2007, 4:30 p.m. to 5:30 p.m.
Agenda: Review of grant applications.
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
24319
Contact Person: Dr. Paulette, S. Gray,
Executive Secretary, National Cancer
Institute, National Institutes of Health, 6116
Executive Boulevard, 8th Floor, Room 8001,
Bethesda, MD 20892–8327, (301) 496–5147.
Name of Committee: National Cancer
Advisory Board.
Date: June 15, 2007, 8 a.m. to 12 p.m.
Agenda: Program reports and
presentations; Business of the Board.
Place: National Cancer Institute, 9000
Rockville Pike, Building 31, C Wing, 6th
Floor, Conference Room 10, Bethesda, MD
20892.
Contact Person: Dr. Paulette S. Gray,
Executive Secretary, National Cancer
Institute, National Institutes of Health, 6116
Executive Boulevard, 8th Floor, Room 8001,
Bethesda, MD 20892–8327, (301) 496–5147.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page:
deainfo.nci.nih.gov/advisory/ncab.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: April 25, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–2146 Filed 5–1–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Research
Resources; Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended ( 5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
E:\FEDREG\02MYN1.LOC
02MYN1
]]>Agencies
[Federal Register Volume 72, Number 84 (Wednesday, May 2, 2007)]
[Notices]
[Pages 24318-24319]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-2144]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Fogarty International Center; Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of
the
[[Page 24319]]
Fogarty International Center Advisory Board.
The meeting will be open to the public as indicated below, with
attendance limited to space available. Individuals who plan to attend
and need special assistance, such as sign language interpretation or
other reasonable accommodations, should notify the Contact Person
listed below in advance of the meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and/or contract proposals
and the discussions could disclose confidential trade secrets or
commercial property such as patentable material, and personal
information concerning individuals associated with the grant
applications and/or contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Fogarty International Center Advisory Board.
Date: May 21-22, 2007.
Closed: May 21, 2007, 1 p.m. to 5 p.m.
Agenda: To review and evaluate grant applications and/or
proposals.
Place: National Institutes of Health, Lawton Chiles
International House, Bethesda, MD 20892.
Open: May 22, 2007, 8:30 a.m. to 5 p.m.
Agenda: Fogarty International Center will present an early draft
of the Strategic Plan.
Place: National Institutes of Health, Lawton Chiles
International House, Bethesda, MD 20892.
Contact Person: Jean L. Flagg-Newton, Ph.D., Special Assistant
to the Director, FIC, Fogarty International Center, National
Institutes of Health, 9000 Rockville Pike, Building 31, Room B2C29,
Bethesda, MD 20892, (301) 496-2968, flaggnej@mail.nih.gov.
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one
form of identification (for example, a government-issued photo ID,
driver's license, or passport) and to state the purpose of their
visit.
Information is also available on the Institute's/Center's home
page: https://www.nih.gov/fic/about/advisory.html, where an agenda
and any additional information for the meeting will be posted when
available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.106,
Minority International Research Training Grant in the Biomedical and
Behavioral Sciences; 93.154, Special International Postdoctoral
Research Program in Acquired Immunodeficiency Syndrome; 93.168,
International Cooperative Biodiversity Groups Program; 93.934,
Fogarty International Research Collaboration Award; 93.989, Senior
International Fellowship Awards Program, National Institutes of
Health, HHS)
Dated: April 24, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 07-2144 Filed 5-1-07; 8:45 am]
BILLING CODE 4140-01-M
